Amivantamab and Lazertinib Approved for First-Line Treatment: Subcutaneous Formulation Available
For patients battling advanced non-small cell lung cancer (NSCLC), the burden of treatment often extends beyond the disease itself. The hours spent tethered to intravenous (IV) drips in infusion centers can be as taxing as the medication, often accompanied by challenging infusion-related reactions that disrupt daily life. A significant shift in the treatment landscape has … Read more